| Antigenics Sees Encouraging Results; Good Long Term Pick VFC submits: It's been a long road for Antigenics (AGEN) since announcing that Russia had approved Oncophage for the treatment of kidney cancer in April of 2008, based on a subset of patients from a Phase III trial. Although the trial results were not thought to be encouraging enough to be brought before the US FDA, Antigenics applied for approval in Europe based on the same subset data that convinced Russia to approve, but were denied this time, sending the AGEN stock back to the sub-$1 level after having had an impressive run during 2009.After trading at those levels for most of 2010, AGEN had a bit of a bounce back of late, hitting as high as just over $1.70, although no significant news had been released to spur such a spike in price.Complete Story » seekingalpha.com |
Patients Crowd Downtown ERs Emergency rooms in downtown Manhattan have become more crowded since St. Vincent's Hospital closed in April. online.wsj.com |
Do Not Get Caught Short Small or Mid Cap Tech There’s a very simple equation taking place in this market right now and I wouldn’t be fighting against it. Here’s how it goes. Big cap tech firms have an enormous amount of cash on their balance sheets and are coming off some of the best couple of quarters they’ve ever had. Growth has been very good for these companies, but they are obviously scared that in a weakening domestic economy it may be hard to keep up the page organically.Complete Story » seekingalpha.com |
What Analysts Won't Tell You About Arena KLLJ Investments submits: Analysts have a job to do, but it isn’t to look out for the retail investor. It is to align expectations with an Investment Bank or Institutions strategy for making money. You will never see an estimate come out of one of the major firms that is on the surface, an audacious prediction. That isn’t to say they don’t forecast aggressive revenue targets internally, but they are for their own consumption and not of a retail investor. Instead, they put out conservative targets and conservative revenue estimates. They come up with negative biases or ‘fear, uncertainty and doubt’ to cap expectations and the share price. They are in this game to make themselves and their wealthy clients’ money, not Joe Investor. That is why you will never see one analyst come out and say what the real value of a Safe and Effective weight loss drug’s potential is. Instead, they will say that weight loss drugs in the past haven’t done well so Arena’s (ARNA) Lorqess will only do a few hundred million dollars instead of pointing out the reasons for current and past weight loss drug failures, which Lorqess has overcome. They’ll come out with FUD (fear, uncertainty and doubt) on how efficacy wasn’t great and use placebo adjusted weight loss figures instead of actual weight loss percentages. They’ll say that 8% weight loss isn’t that meaningful. All of this to keep the share price in check. How wrong they are, and they may even know it. Why do you think Arena’s institutional interest is so high? Even when ARNA was trading at $3 it was high. Do you know how hard it is for institutions to justify investing millions in a $3 stock? Arena underscores the reason why investors have to perform their own extensive due diligence. You can’ t relay on headlines or analyst opinions if you want to make money. Complete Story » seekingalpha.com |
PPD and VirtualScopics Establish Strategic Alliance for Medical Imaging Services [Business Wire] - PPD, Inc. and VirtualScopics, Inc. today announced a strategic alliance to deliver a comprehensive set of clinical and medical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of their oncology compounds, creating time and cost efficiencies. us.rd.yahoo.com |